Key Inclusion Criteria:

          1. The patient must voluntarily participate in this clinical study. Be willing and able
             to provide written informed consent form (ICF) prior to any study activity.

          2. Age ≥18 years on the day of signing the ICF (either from screening period for dose
             escalation stage or from pre-screening period for dose expansion stage), males or
             females.

          3. The enrolled patients must have histologically or cytologically confirmed advanced
             solid tumor that is refractory to standard treatment or for which no standard
             treatment exists. The patients with known microsatellite-instability high (MSI- H) or
             deficient in mismatch repair (dMMR) disease are required to have received prior PD
             1/PD-L1 therapy; those with known NTRK fusion are required to have received an
             approved TRK-inhibitor. The patients who are suitable for resection or other localized
             therapy that is potentially curative are not eligible.

        Key Exclusion Criteria:

          1. Patients with active or untreated known CNS metastases and/or carcinomatous meningitis
             should be excluded.

          2. Patients with serious acute or chronic infections.

          3. Patients who have received prescription or non-prescription drugs or other products
             known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow
             therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 which
             cannot be discontinued 7 days prior to Day 1 of dosing and withheld throughout the
             study until 2 weeks after the last dose of IMP7068.

          4. Patients who are participating in or have participated in a study of an
             investigational agent and received study therapy or used an investigational device
             within 28 days of the first dose of treatment.

          5. Patients have not recovered (i.e., to Grade ≤1 or to baseline, as evaluated by
             NCI-CTCAE Version 5.0) from prior anti-cancer therapy-induced AEs, except for
             alopecia.

          6. Patients who have undergone a major surgery or have undergone a radical radiotherapy
             within 28 days prior to the study treatment, or have undergone a palliative
             radiotherapy within 14 days prior to the study treatment, or have used a radioactive
             drug (Strontium, Samarium, etc.) within 56 days prior to the study treatment.

          7. Patients who are unable to swallow oral medications. Patients have gastrointestinal
             illnesses that may clinically significantly affect the absorption of oral medication
             IMP7068 at discretion of investigators.